{"id":277,"date":"2026-03-31T16:19:02","date_gmt":"2026-03-31T16:19:02","guid":{"rendered":"https:\/\/kstories.kr\/en-ko\/tec260331010-enkr\/"},"modified":"2026-03-31T16:19:02","modified_gmt":"2026-03-31T16:19:02","slug":"tec260331010-enkr","status":"publish","type":"post","link":"https:\/\/kstories.kr\/en-ko\/tec260331010-enkr\/","title":{"rendered":"GC Cell Files CAR-NK \uae30\uc220 \ud2b9\ud5c8, Expanding Possibilities for Solid Cancer \uce58\ub8cc"},"content":{"rendered":"
\n
GC Cell Files \ud2b9\ud5c8 \ucd9c\uc6d0 for CAR-NK Immunotherapy \uae30\uc220 Targeting \uace0\ud615\uc554<\/div>\n
\"Image\"<\/div>\n

GC Cell Co-CEOs Kim Jae-wang and Won Sung-yong announced on the 31st that it has filed a \ud2b9\ud5c8 \ucd9c\uc6d0 related to \uba74\uc5ed\uce58\ub8cc for the \uce58\ub8cc of \uace0\ud615\uc554. This is a \ud30c\uc774\ud504\ub77c\uc778 developed based on GC Cells CAR-NK \ud50c\ub7ab\ud3fc, targeting CLDN18.2, and is considered a significant expansion of its applicability to the \ubd84\uc57c of \uace0\ud615\uc554.<\/p>\n

\ud2b9\ud5c8 \ucd9c\uc6d0 for Solid Cancer-Targeting CAR-NK \uae30\uc220<\/h2>\n

GC Cell recently filed a \ud2b9\ud5c8 \ucd9c\uc6d0 for \uba74\uc5ed\uce58\ub8cc \uae30\uc220 aimed at treating \uace0\ud615\uc554. This \ud2b9\ud5c8 was developed by utilizing GC Cells proprietary CAR-NK Chimeric Antigen Receptor-Natural Killer cell \ud50c\ub7ab\ud3fc to target a specific \ub2e8\ubc31\uc9c8, CLDN18.2.<\/p>\n

This \uae30\uc220 is highly significant because it extends beyond the limitations of existing \uba74\uc5ed\uce58\ub8cc\uc81c, which primarily targeted \ud608\uc561\uc554, to expand applicability to the challenging \ubd84\uc57c of \uace0\ud615\uc554. Through this \ud2b9\ud5c8, GC Cell aims to gain a competitive \uc6b0\uc704 in the \uac1c\ubc1c of solid cancer \uce58\ub8cc\uc81c.<\/p>\n

CLDN18.2 \ub2e8\ubc31\uc9c8 Expressed in Major \uace0\ud615\uc554<\/h2>\n

CLDN18.2, the key target of this \uae30\uc220, is known to be a \ub2e8\ubc31\uc9c8 commonly expressed in various \uace0\ud615\uc554, including gastric cancer, pancreatic cancer, and esophageal cancer. This \ub2e8\ubc31\uc9c8 has been identified as playing a crucial role in \uc554\uc138\ud3ec \uc131\uc7a5 and is currently attracting significant \uc8fc\ubaa9 as a new therapeutic \ud45c\uc801 in the global pharmaceutical and biotechnology \uc0b0\uc5c5.<\/p>\n

The \uac1c\ubc1c of \uce58\ub8cc\ubc95 targeting CLDN18.2 is expected to offer new \uce58\ub8cc \uc635\uc158 for \ud658\uc790 with \uace0\ud615\uc554. GC Cells \ud2b9\ud5c8 \ucd9c\uc6d0 is analyzed to be in line with these global \uc5f0\uad6c \ub3d9\ud5a5.<\/p>\n

Strengths and Expandability of CAR-NK \uce58\ub8cc\uc81c<\/h2>\n

Unlike CAR-T Chimeric Antigen Receptor-T cell \uce58\ub8cc\uc81c, which use a \ud658\uc790s own \uc138\ud3ec, CAR-NK \uce58\ub8cc\uc81c utilize \uc138\ud3ec from healthy \uae30\uc99d\uc790. This characteristic offers the \uc7a5\uc810 of being developed as a mass-producible, off-the-shelf \uce58\ub8cc\uc81c.<\/p>\n

Furthermore, high \uc548\uc804\uc131 is expected based on the innate immune \ud2b9\uc131 of NK \uc138\ud3ec. It is regarded as an \ub300\uc548 that can contribute to reducing \uce58\ub8cc \ube44\uc6a9 and improving \ud658\uc790 \uc811\uadfc\uc131 through \ud6a8\uc728\uc131 in \uc0dd\uc0b0 and \uacf5\uae09.<\/p>\n

Strengthening Global \uacbd\uc7c1\ub825 and Continued \uc5f0\uad6c \uac1c\ubc1c<\/h2>\n

Won Sung-yong, CEO of GC Cell, stated, This \ud2b9\ud5c8 is one of the continuous \uc131\uacfc in the \uc5f0\uad6c \uac1c\ubc1c of our CAR-NK \ud50c\ub7ab\ud3fc-based solid cancer \ud30c\uc774\ud504\ub77c\uc778.<\/p>\n

GC Cell announced its \uacc4\ud68d to continue pursuing relevant \uc5f0\uad6c \uac1c\ubc1c to further strengthen its global \uacbd\uc7c1\ub825.<\/p>\n

Through this \ud2b9\ud5c8 \ucd9c\uc6d0, GC Cell is expected to secure a leading \uc785\uc9c0 in the \ubd84\uc57c of solid cancer \uba74\uc5ed\uce58\ub8cc and provide innovative \uce58\ub8cc \ub300\uc548 to solid cancer \ud658\uc790 worldwide. GC Cell \uacc4\ud68d to continue leading the next-generation \uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5 through ongoing \uc5f0\uad6c \uac1c\ubc1c.<\/p>\n

\n
\uc774 \uae30\uc0ac\uc5d0 \uc0ac\uc6a9\ub41c \ud55c\uad6d\uc5b4 \uc6a9\uc5b4<\/div>\n
\ud2b9\ud5c8 \ucd9c\uc6d0(Patent Application), \ud2b9\ud5c8(Patent), \uae30\uc220(Technology), \uace0\ud615\uc554(Solid Cancers), \uce58\ub8cc(Treatment), \uba74\uc5ed\uce58\ub8cc(Immunotherapy), \ud30c\uc774\ud504\ub77c\uc778(Pipeline), \ud50c\ub7ab\ud3fc(Platform), \ubd84\uc57c(Field), \uc785\uc9c0(Position), \uce58\ub8cc \ub300\uc548(Treatment Alternatives), \ub300\uc548(Alternative), \ud658\uc790(Patients), \uacc4\ud68d(Plan), \uc138\ud3ec(Cells), \uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5(Cell Therapy Market), \uce58\ub8cc\uc81c(Treatments), \uc5f0\uad6c \uac1c\ubc1c(R&D), \uac1c\ubc1c(Development), \ub2e8\ubc31\uc9c8(Protein), \uba74\uc5ed\uce58\ub8cc\uc81c(Immunotherapies), \ud608\uc561\uc554(Blood Cancers), \uc6b0\uc704(Edge), \uc554\uc138\ud3ec \uc131\uc7a5(Cancer Cell Growth), \uc8fc\ubaa9(Attention), \ud45c\uc801(Target), \uc0b0\uc5c5(Industry), \uce58\ub8cc\ubc95(Therapies), \uce58\ub8cc \uc635\uc158(Treatment Options), \uc5f0\uad6c \ub3d9\ud5a5(Research Trends), \uae30\uc99d\uc790(Donors), \uc7a5\uc810(Advantage), \uc548\uc804\uc131(Safety), \ud2b9\uc131(Characteristics), \uce58\ub8cc \ube44\uc6a9(Treatment Costs), \ud658\uc790 \uc811\uadfc\uc131(Patient Accessibility), \ud6a8\uc728\uc131(Efficiency), \uc0dd\uc0b0(Manufacturing), \uacf5\uae09(Supply), \uacbd\uc7c1\ub825(Competitiveness), \uc131\uacfc(Achievements)<\/div>\n<\/div>\n
English version<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GC Cell Files \ud2b9\ud5c8 \ucd9c\uc6d0 for CAR-NK Immunotherapy \uae30\uc220 Targeting \uace0\ud615\uc554 GC Cell Co-CEOs Kim Jae-wang and Won Sung-yong announced…<\/p>\n","protected":false},"author":11,"featured_media":276,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[293,292,295,294],"class_list":["post-277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech-economy","tag-car-nk","tag-gc-cell","tag-immunotherapy","tag-solid-cancer"],"_links":{"self":[{"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/posts\/277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/comments?post=277"}],"version-history":[{"count":0,"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/posts\/277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/media\/276"}],"wp:attachment":[{"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/media?parent=277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/categories?post=277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kstories.kr\/en-ko\/wp-json\/wp\/v2\/tags?post=277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}